Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3097-3102

  Sereno, D ^a   Cavaleyra, M ^a   Zemzoumi, K ^a   Maquaire, S ^a   Ouaissi, A ^a   Lemesre, J L ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY TARTRATE; CHLOROCRESOL; MEGLUMINE; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CULTURE MEDIUM; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; LEISHMANIA INFANTUM; LEISHMANIASIS; NONHUMAN; PARASITE; PRIORITY JOURNAL;

EID: 0031760626     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3097     Document Type: Article

References (39)

1. Bates, P. A., C. D. Robertson, L. Tetley, and G. H. Coombs. 1992. Cultivation and characterization of Leishmania mexicana amastigote-like forms. Parasitology 105:193-202.
2. Bates, P. A. 1993. Axenic culture of Leishmania amastigotes. Parasitol. Today 9:143-146.
3. Bates, P. A. 1992. Complete developmental cycle of Leishmania mexicana in axenic culture. Parasitology 108:1-9.
4. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy and future strategies. Rev. Infect. Dis. 10:560-586.
5. Berman, J. D., D. Waddell, and B. D. Hanson. 1985. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob. Agents Chemother. 27:916-920.
6. Berman, J. D., J. V. Gallalee, and J. M. Best. 1987. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta oxidation in Leishmania mexicana amastigotes. Biochem. Pharmacol. 36:197-201.
7. Burguera, J. L., M. Burguera, Y. Petit de Pena, A. Lugo, and N. Anez. 1993. Selective determination of antimony(III) and antimony(V) in serum and urine and of total antimony in skin biopsies of patients with cutaneous leishmaniasis treated with meglumine antimoniate. Trace Elem. Med. 10:66-70.
8. Callahan, H. L., A. C. Portal, R. Devereaux, and M. Grögl. 1997. An axenic amastigote system for drug screening. Antimicrob. Agents Chemother. 41: 818-822.
9. Coombs, G. H., J. A. Craft, and D. T. Hart. 1982. A comparative study of Leishmania mexicana amastigotes and promastigotes. Enzyme activities and subcellular locations. Mol. Biochem. Parasitol. 5:199-211.
10. Coombs, G. H., L. Tetley, V. A. Moss, and K. Vickerman. 1986. Three-dimensional structure of the Leishmania amastigote as revealed by computer-aided reconstruction from serial sections. Parasitology 92:13-23.
11. Ephros, M., E. Waldman, and D. Zilberstein. 1997. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob. Agents Chemother. 41:1064-1068.
12. Faraut-Gambarelli, F., R. Piarroux, M. Deniau, B. Giusano, P. Marty, G. Michel B. Faugère, and H. Dumon. 1997. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 41:827-830.
13. Gebre-Hiwot, A., G. Tadesse, S. L. Croft, and D. Frommel. 1992. An in vitro model for screening antileishmanial drugs: the human leukemia monocyte cell line, THP-1. Acta Trop. 51:237-245.
14. ® (sodium stibogluconate); a 50-year personal reminiscence. Trans. R. Soc. Trop. Med. Hyg. 89:339-341.
15. Goodwin, L. G., and J. E. Page. 1943. A study of the excretion of organic antimonials using a polarographic procedure. Biochem. J. 22:236-40.
16. Grögl, M. T. N. Thomason, and E. Franke. 1992. Drug resistance in leishmaniasis: it's implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:117-126.
17. Hassan, H. F., and G. H. Coombs. 1985. Leishmania mexicana, purine metabolizing enzymes of amastigotes and promastigotes. Exp. Parasitol. 59:15-28.
18. 50 in studies of drug resistance of malaria parasites. Acta Trop. 55:257-261.
19. Lemesre, J. L., D. Sereno, S. Daulouède, B. Veyret, N. Brajon, and P. Vincendeau. 1997. Leishmania spp.: nitric oxide-mediated metabolic inhibition of promastigote and axenically-grown amastigote forms. Exp. Parasitol. 86:58-68.
20. Lemesre, J. L. 1994. Methods for the culture in vitro of different stages of tissue parasites. International publication no. WO 94/26899. Pending patent PCT/FR94/00577.
21. Martinez, S., D. L. Looker, and J. J. Marr. 1988. A tissue culture system for the growth of several species of Leishmania: growth kinetics and drug sensitivities. Am. J. Trop. Med. Hyg. 38:304-307.
22. Mattock, N. M., and W. Peters. 1975. The experimental chemotherapy of leishmaniasis. II. The activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use. Ann. Trop. Med. Parasitol. 69:359-371.
23. Mottram, J. C., and G. H. Coombs. 1985. Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp. Parasitol. 59:151-160.
24. Ouellette, M., and B. Papadopoulou. 1993. Mechanisms of drug resistance in Leishmania. Parasitol. Today 9:150-153.
25. Peters, B. S., D. Fish, R. Golden, D. A. Evans, A. D. M. Bryceson, and A. J. Pinching. 1990. Visceral leishmaniasis in HIV infection and AIDS: clinical feature and response to therapy. Q. J. Med. 77:1101-1111.
26. Petit de Pena, Y., M. Gallignani, M. Burguera, J. L. Burguera, N. Anez, and Y. Lugo. 1990. Selective determination of antimony(III) and antimony(V) in blood serum and urine by hydride generation and atomic absorption spectrometry. J. Braz. Chem. Soc. 1:72-75.
27. Rainey, P. M., T. W. Spithill, D. McMahon-Pratt, and A. A. Pan. 1991. Biochemical and molecular characterization of Leishmania pifanoi amastigotes in continuous axenic culture. Mol. Biochem. Parasitol. 49:111-118.
28. Rees, P. H., M. I. Keating, P. A. Kager, and W. T. Hockmeyer. 1980. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet ii:226-229.
29. Roberts, W. L., and P. M. Rainey. 1993. Antileishmanial activity of sodium stibogluconate fractions. Antimicrob. Agents Chemother. 37:1842-1846.
30. Roberts, W. L., and P. M. Rainey. 1993. Antimony quantification in Leishmania by electrothermal atomic absorption spectroscopy. Anal. Biochem. 211:1-6.
31. Roberts, W. L., J. D. Berman, and P. M. Rainey. 1995. In vitro antileishmanial properties of tri-and pentavalent antimonial preparations. Antimicrob. Agents Chemother. 39:1234-1239.
32. Sereno, D., and J. L. Lemesre. 1997. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents Chemother. 41:972-976.
33. Sereno, D., and J. L. Lemesre. 1997. In vitro life cycle of pentamidine-resistant amastigotes: stability of the chemoresistant phenotypes is dependent on the level of resistance induced. Antimicrob. Agents Chemother. 41:1898-1903.
34. Sereno, D., and J. L. Lemesre. 1997. Use of an enzymatic in vitro micro-method to quantify amastigote stage of axenically grown amastigote forms of Leishmania amazonensis. Parasitol. Res. 83:401-403.
35. Sereno, D., P. Michon, N. Brajon, and J. L. Lemesre. 1997. Phenotypic characterization of Leishmania mexicana pentamidine-resistant promastigotes: modulation of the resistance during developmental life cycle. C. R. Acad. Sci. 320:981-987.
36. Tsuchiya, S., Y. Kobayashi, Y. Goto, H. Okumara, S. Nakal, T. Konno, and K. Tada. 1982. Induction of maturation in cultured human monocytic leu-kemia cells by phorbol diester. Cancer Res. 42:1530-1536.
37. Ullman, B. 1995. Multidrug resistance and P-glycoproteins in parasitic protozoa. J. Bioenergetic. Biomembranes 27:77-84.
38. Ullman, B., E. Carrero-Valenzuella, and T. Coons. 1989. Leishmania donovani: isolation and characterization of sodium stibogluconate (Pentostam)-resistant cell lines. Exp. Parasitol. 69:157-163.
39. Valladares, J. E., J. Arebolla, M. Esteban, and M. Arbois. 1996. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs. Vet. Res. 138:181-183.